Carboprost

Amneal Expands Injectables Portfolio with 4 New Products

Retrieved on: 
Thursday, February 17, 2022
Health, FDA, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, NYSE, Patient, Food, Risk, Carboprost, Company, Federation, CGT, Weather, Injection, Forward-looking statement, Medication, U.S. Securities and Exchange Commission, Security (finance), Baclofen, Annual report, Degenerative disease, SVP, Regulation of tobacco by the U.S. Food and Drug Administration, Tris, Abbreviated New Drug Application, USP, FDA, Saol, Generic, ANDA, Central nervous system, LVP, Private Securities Litigation Reform Act, Growth, Dexamethasone, Research, Investment, Amneal Pharmaceuticals, COVID-19, Azacitidine, Atropine, Peptide, Pharmaceutical industry, Fine chemical, Generic drug, Risk management

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (Amneal or the Company) today announced the approval of four generic injectables products.

Key Points: 
  • Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (Amneal or the Company) today announced the approval of four generic injectables products.
  • An important element of Amneals long-term growth strategy is expanding our injectables business, and todays announcement of four new approvals is another key step.
  • The Company has a diverse portfolio of approximately 250 products in its Generics segment and is expanding across a broad range of complex products and therapeutic areas, including injectables and biosimilars.
  • In its Specialty segment, Amneal has a growing portfolio of branded pharmaceutical products focused primarily on central nervous system and endocrine disorders, with a pipeline focused on unmet needs.

Fresenius Kabi Issues Voluntary Nationwide Recall of 13 Lots of Ketorolac Tromethamine Injection, USP Due to the Presence of Particulate Matter in Reserve Samples

Retrieved on: 
Monday, April 20, 2020
Health, Pharmaceutical, Drugs, Psychoactive drugs, RTT, Analgesics, Amines, Nonsteroidal anti-inflammatory drugs, Ketorolac, Syntex, Tris, Carboprost, Ketamine, Health, Pharmaceutical, Drugs, Psychoactive drugs, RTT, Analgesics, Amines, Nonsteroidal anti-inflammatory drugs, Ketorolac, Syntex, Tris, Carboprost, Ketamine

Particulate matter was found in eight reserve sample vials.

Key Points: 
  • Particulate matter was found in eight reserve sample vials.
  • View the full release here: https://www.businesswire.com/news/home/20200420005634/en/
    Fresenius Kabi USA, LLC is voluntarily recalling 13 lots of Ketorolac Tromethamine Injection, USP, 60 mg/2 mL (30 mg/mL), 2 mL fill in a 2 mL amber vial to the user level due to the presence of particulate matter.
  • Ketorolac Tromethamine, a nonsteroidal anti-inflammatory drug, is indicated for the short-term (up to 5 days in adults) management of moderately severe acute pain that requires analgesia at the opioid level.
  • The total combined duration of use of oral Ketorolac Tromethamine and Ketorolac Tromethamine injection should not exceed 5 days.

Dr. Reddy's Laboratories Announces First-to-market Launch of Carboprost Tromethamine Injection USP, 250 mcg/mL (1mL) Single-dose Vial in the U.S. Market

Retrieved on: 
Wednesday, July 3, 2019
FDA, Pharmaceutical, Health, Carboprost, Prostaglandins, Tris, Uterotonic, Injection, Chemistry, Physical sciences, Health

The Hemabate injection, 250 mcg/mL brand had U.S. sales of approximately $55 million MAT for the most recent twelve months ending in April 2019 according to IQVIA Health*.

Key Points: 
  • The Hemabate injection, 250 mcg/mL brand had U.S. sales of approximately $55 million MAT for the most recent twelve months ending in April 2019 according to IQVIA Health*.
  • Dr. Reddys Carboprost Tromethamine Injection USP, 250 mcg/mL (1mL) contains carboprost tromethamine equivalent to 250 mcg of carboprost.
  • Carboprost Tromethamine Injection sterile solution (carboprost tromethamine) like other potent oxytocic agents, should be used only with strict adherence to recommended dosages.
  • Carboprost Tromethamine Injection should be used by medically trained personnel in a hospital which can provide immediate intensive care and acute surgical facilities.